EW

Edwards Lifesciences Corporation

Company Overview

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

SectorHealthcare
IndustryMedical - Devices
Market Cap$51.8B
Employees16,000
CEOBernard J. Zovighian

Valuation

Current Price$89.9
Fair Value?$000.00
Valuation?Overvalued
Hist. PE ?35.73
EPS (TTM) ?1.74
Forward EPS Growth ?11.42%
Historical Growth ?15.28%
Equity, FCF, Long Term Debt, Net Profit, and Shares Outstanding history charts are available on the Pro plan for just $9.99/month.Sign in to unlock Pro

Price

Unlock Fair Value line — Pro

EPS

Revenue

Equity

Pro

Available on the Pro plan

Free Cash Flow

Pro

Available on the Pro plan

Long Term Debt

Pro

Available on the Pro plan

Net Profit

Pro

Available on the Pro plan

Shares Outstanding

Pro

Available on the Pro plan

Last updated: 9/5/2026, 6:12:39 PM